FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102435584> ?p ?o ?g. }

• W2102435584 endingPage "487" @default.
• W2102435584 startingPage "481" @default.
• W2102435584 abstract "<h3>OBJECTIVE</h3> To review our experience with low dose intravenous pulse cyclophosphamide in the treatment of patients with severe connective tissue diseases. <h3>PATIENTS</h3> Ninety patients (68F:22M) with severe connective tissue diseases received a total of 883 cyclophosphamide pulses with 78 of 90 patients initially having weekly 500 mg pulses for a median of three (2–10) weeks. Diagnoses included: systemic lupus erythematosus (SLE) (n=43); systemic vasculitides (n=42); idiopathic inflammatory myopathies (n=4); mixed essential cryoglobulinaemic vasculitis (n=1). The median age was 48 (range 22–76) years with a median disease duration of 94 (18–250) months. <h3>RESULTS</h3> Complete or partial remission was noted in 68 of 90 patients (75.5%) after a median follow up of 56 (5–213) months. At follow up significant median changes were noted in SLE patients: erythrocyte sedimentation rate (ESR) from 44 to 22 mm 1st hour; anti-dsDNA antibody concentrations from 81 to 48 IU/ml; proteinuria from 2.5 to 1.5 g/day; serum albumin from 36 to 40 g/l; complement C3 from 0.88 to 0.90 g/l, and C4 from 0.18 to 0.22 g/l. In the vasculitis patients significant median changes were seen in: ESR from 44 to 15 mm 1st hour; C reactive protein (CRP) from 16 to 5 g/dl; neutrophils from 8.55 to 4.3 × 10⁹/l; platelets from 340 to 261 × 10³/l, and haemoglobin from 12.6 to 13.2 g/dl. Patients with Churg-Strauss syndrome, Wegener’s granulomatosis, and neuropsychiatric lupus showed the best initial response but 58% of Wegener’s patients relapsed. Median corticosteroid doses were significantly reduced from 15 (5–60) mg to 10 (3–35) mg daily. Adverse events: infections (7 patients), neutropenia (5), lymphopenia (18), and haemorrhagic cystitis (1 intravenous and 2 oral cyclophosphamide), allergies to mesna (2). None of the women at risk had prolonged amenorrhoea. Five patients doubled their serum creatinine and five died from sepsis (2) or severe disease (3). <h3>CONCLUSION</h3> Treatment of severe connective tissue diseases with ‘low dose’ intravenous cyclophosphamide pulses compares in efficacy with the higher monthly doses previously advocated. Treatment was well tolerated with fewer adverse effects and most significantly, there were no cases of premature ovarian failure." @default.
• W2102435584 created "2016-06-24" @default.
• W2102435584 creator A5002302478 @default.
• W2102435584 creator A5017970332 @default.
• W2102435584 creator A5025335653 @default.
• W2102435584 creator A5040146041 @default.
• W2102435584 creator A5043181396 @default.
• W2102435584 creator A5082179979 @default.
• W2102435584 date "1997-08-01" @default.
• W2102435584 modified "2023-10-03" @default.
• W2102435584 title "Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide" @default.
• W2102435584 cites W1914343637 @default.
• W2102435584 cites W1971058219 @default.
• W2102435584 cites W1981707384 @default.
• W2102435584 cites W1982860902 @default.
• W2102435584 cites W1989431701 @default.
• W2102435584 cites W2011309580 @default.
• W2102435584 cites W2013832829 @default.
• W2102435584 cites W2021400852 @default.
• W2102435584 cites W2038691289 @default.
• W2102435584 cites W2049831025 @default.
• W2102435584 cites W2053582855 @default.
• W2102435584 cites W2068516328 @default.
• W2102435584 cites W2070655720 @default.
• W2102435584 cites W2071027536 @default.
• W2102435584 cites W2086003187 @default.
• W2102435584 cites W2109207289 @default.
• W2102435584 cites W2113895275 @default.
• W2102435584 cites W2132810296 @default.
• W2102435584 cites W2135212798 @default.
• W2102435584 cites W2137303532 @default.
• W2102435584 cites W2146203649 @default.
• W2102435584 cites W2312254946 @default.
• W2102435584 cites W2325870812 @default.
• W2102435584 cites W2336339060 @default.
• W2102435584 cites W2972987 @default.
• W2102435584 cites W4290408609 @default.
• W2102435584 cites W46709147 @default.
• W2102435584 doi "https://doi.org/10.1136/ard.56.8.481" @default.
• W2102435584 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1752422" @default.
• W2102435584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9306871" @default.
• W2102435584 hasPublicationYear "1997" @default.
• W2102435584 type Work @default.
• W2102435584 sameAs 2102435584 @default.
• W2102435584 citedByCount "114" @default.
• W2102435584 countsByYear W21024355842012 @default.
• W2102435584 countsByYear W21024355842013 @default.
• W2102435584 countsByYear W21024355842014 @default.
• W2102435584 countsByYear W21024355842015 @default.
• W2102435584 countsByYear W21024355842016 @default.
• W2102435584 countsByYear W21024355842017 @default.
• W2102435584 countsByYear W21024355842018 @default.
• W2102435584 countsByYear W21024355842019 @default.
• W2102435584 countsByYear W21024355842020 @default.
• W2102435584 countsByYear W21024355842021 @default.
• W2102435584 countsByYear W21024355842022 @default.
• W2102435584 countsByYear W21024355842023 @default.
• W2102435584 crossrefType "journal-article" @default.
• W2102435584 hasAuthorship W2102435584A5002302478 @default.
• W2102435584 hasAuthorship W2102435584A5017970332 @default.
• W2102435584 hasAuthorship W2102435584A5025335653 @default.
• W2102435584 hasAuthorship W2102435584A5040146041 @default.
• W2102435584 hasAuthorship W2102435584A5043181396 @default.
• W2102435584 hasAuthorship W2102435584A5082179979 @default.
• W2102435584 hasBestOaLocation W21024355841 @default.
• W2102435584 hasConcept C126322002 @default.
• W2102435584 hasConcept C142724271 @default.
• W2102435584 hasConcept C159654299 @default.
• W2102435584 hasConcept C203014093 @default.
• W2102435584 hasConcept C2775915377 @default.
• W2102435584 hasConcept C2776015282 @default.
• W2102435584 hasConcept C2776153627 @default.
• W2102435584 hasConcept C2776670291 @default.
• W2102435584 hasConcept C2776694085 @default.
• W2102435584 hasConcept C2776755627 @default.
• W2102435584 hasConcept C2777575956 @default.
• W2102435584 hasConcept C2778143017 @default.
• W2102435584 hasConcept C2779075594 @default.
• W2102435584 hasConcept C2779134260 @default.
• W2102435584 hasConcept C2779561371 @default.
• W2102435584 hasConcept C2780091579 @default.
• W2102435584 hasConcept C518705261 @default.
• W2102435584 hasConcept C71924100 @default.
• W2102435584 hasConcept C90924648 @default.
• W2102435584 hasConceptScore W2102435584C126322002 @default.
• W2102435584 hasConceptScore W2102435584C142724271 @default.
• W2102435584 hasConceptScore W2102435584C159654299 @default.
• W2102435584 hasConceptScore W2102435584C203014093 @default.
• W2102435584 hasConceptScore W2102435584C2775915377 @default.
• W2102435584 hasConceptScore W2102435584C2776015282 @default.
• W2102435584 hasConceptScore W2102435584C2776153627 @default.
• W2102435584 hasConceptScore W2102435584C2776670291 @default.
• W2102435584 hasConceptScore W2102435584C2776694085 @default.
• W2102435584 hasConceptScore W2102435584C2776755627 @default.
• W2102435584 hasConceptScore W2102435584C2777575956 @default.
• W2102435584 hasConceptScore W2102435584C2778143017 @default.
• W2102435584 hasConceptScore W2102435584C2779075594 @default.
• W2102435584 hasConceptScore W2102435584C2779134260 @default.

• next